Please select the option that best describes you:
What is your approach to treatment of mantle cell lymphoma in someone with a mutated gene downstream of the BTK receptor, such as mutated CARD11?
Have you seen frontline resistance to BTKi in this case and would you thus go with a chemo based regimen?
Answer from: Medical Oncologist at Academic Institution
For those with primary refractory MCL after a cBTKi, I would still not proceed with chemotherapy, given the limited data to support benefit after a patient progresses on a cBTKi. Only data thus far is with a bendamustine/cytarabine-based regimen, which, if/when they relapse, would potentially impact...
Sign In or Register to read more